C
Integrated Biopharma, Inc.
INBP
$0.3069
$0.01194.03%
C
Hold
2/14/2025Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 2/14/2025 due to a substantial increase in the valuation index, growth index and total return index.
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 2/14/2025 due to a substantial increase in the valuation index, growth index and total return index.
C
Hold
1/22/2025Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C- from C on 1/22/2025 due to a decline in the valuation index.
Integrated Biopharma, Inc. (INBP) was downgraded to C- from C on 1/22/2025 due to a decline in the valuation index.
C
Hold
1/7/2025Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 1/7/2025 due to an increase in the volatility index and total return index.
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 1/7/2025 due to an increase in the volatility index and total return index.
C
Hold
12/2/2024Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C- from D+ on 12/2/2024 due to a significant increase in the valuation index, total return index and volatility index.
Integrated Biopharma, Inc. (INBP) was upgraded to C- from D+ on 12/2/2024 due to a significant increase in the valuation index, total return index and volatility index.
D
Sell
10/24/2024Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to D+ from D on 10/24/2024 due to a significant increase in the growth index and valuation index. EBIT increased 13.24% from $355 to $402.
Integrated Biopharma, Inc. (INBP) was upgraded to D+ from D on 10/24/2024 due to a significant increase in the growth index and valuation index. EBIT increased 13.24% from $355 to $402.
D
Sell
9/18/2023Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to D from D+ on 9/18/2023 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 180.68% from $1.47M to -$1.19M, total revenue declined 0.79% from $13.1M to $12.99M, and total capital declined 0.49% from $21.64M to $21.53M.
Integrated Biopharma, Inc. (INBP) was downgraded to D from D+ on 9/18/2023 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 180.68% from $1.47M to -$1.19M, total revenue declined 0.79% from $13.1M to $12.99M, and total capital declined 0.49% from $21.64M to $21.53M.
D
Sell
6/20/2023Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to D+ from C- on 6/20/2023 due to a decline in the volatility index and valuation index.
Integrated Biopharma, Inc. (INBP) was downgraded to D+ from C- on 6/20/2023 due to a decline in the volatility index and valuation index.
C
Hold
6/7/2023Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C- from C on 6/7/2023 due to a decline in the total return index.
Integrated Biopharma, Inc. (INBP) was downgraded to C- from C on 6/7/2023 due to a decline in the total return index.
C
Hold
5/23/2023Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 5/23/2023 due to an increase in the volatility index.
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 5/23/2023 due to an increase in the volatility index.
C
Hold
5/19/2023Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C- from D on 5/19/2023 due to a major increase in the growth index, volatility index and total return index. Operating cash flow increased 3,440.91% from -$44 to $1.47M, EBIT increased 233.33% from -$33 to $44, and earnings per share increased from -$0.0018 to $0.0005.
Integrated Biopharma, Inc. (INBP) was upgraded to C- from D on 5/19/2023 due to a major increase in the growth index, volatility index and total return index. Operating cash flow increased 3,440.91% from -$44 to $1.47M, EBIT increased 233.33% from -$33 to $44, and earnings per share increased from -$0.0018 to $0.0005.
D
Sell
5/11/2023Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to D from D+ on 5/11/2023 due to a decline in the volatility index, total return index and efficiency index.
Integrated Biopharma, Inc. (INBP) was downgraded to D from D+ on 5/11/2023 due to a decline in the volatility index, total return index and efficiency index.
D
Sell
4/4/2023Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to D+ from C- on 4/4/2023 due to a decline in the volatility index and total return index.
Integrated Biopharma, Inc. (INBP) was downgraded to D+ from C- on 4/4/2023 due to a decline in the volatility index and total return index.
C
Hold
3/20/2023Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C- from D+ on 3/20/2023 due to an increase in the volatility index and solvency index. The quick ratio increased from 0.84 to 1.08.
Integrated Biopharma, Inc. (INBP) was upgraded to C- from D+ on 3/20/2023 due to an increase in the volatility index and solvency index. The quick ratio increased from 0.84 to 1.08.
D
Sell
2/6/2023Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to D+ from C- on 2/6/2023 due to a decline in the volatility index and total return index.
Integrated Biopharma, Inc. (INBP) was downgraded to D+ from C- on 2/6/2023 due to a decline in the volatility index and total return index.
C
Hold
1/20/2023Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C- from D+ on 1/20/2023 due to an increase in the volatility index.
Integrated Biopharma, Inc. (INBP) was upgraded to C- from D+ on 1/20/2023 due to an increase in the volatility index.
D
Sell
11/16/2022Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to D+ from C on 11/16/2022 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from $0.05 to -$0.0012, EBIT declined 93.15% from $438 to $30, and operating cash flow declined 63.3% from $2.7M to $992.
Integrated Biopharma, Inc. (INBP) was downgraded to D+ from C on 11/16/2022 due to a significant decline in the growth index, volatility index and total return index. Earnings per share declined from $0.05 to -$0.0012, EBIT declined 93.15% from $438 to $30, and operating cash flow declined 63.3% from $2.7M to $992.
C
Hold
6/9/2022Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 6/9/2022 due to a decline in the volatility index and total return index.
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 6/9/2022 due to a decline in the volatility index and total return index.
C
Hold
5/18/2022Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C+ from C on 5/18/2022 due to an increase in the total return index and solvency index. Debt to equity declined from 0.23 to 0.19, and the quick ratio increased from 0.6 to 0.7.
Integrated Biopharma, Inc. (INBP) was upgraded to C+ from C on 5/18/2022 due to an increase in the total return index and solvency index. Debt to equity declined from 0.23 to 0.19, and the quick ratio increased from 0.6 to 0.7.
C
Hold
5/12/2022Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 5/12/2022 due to a decline in the volatility index and total return index.
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 5/12/2022 due to a decline in the volatility index and total return index.
C
Hold
4/18/2022Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C+ from B- on 4/18/2022 due to a decline in the total return index and volatility index.
Integrated Biopharma, Inc. (INBP) was downgraded to C+ from B- on 4/18/2022 due to a decline in the total return index and volatility index.
B
Buy
3/21/2022Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to B- from B on 3/21/2022 due to a significant decline in the total return index and volatility index.
Integrated Biopharma, Inc. (INBP) was downgraded to B- from B on 3/21/2022 due to a significant decline in the total return index and volatility index.
B
Buy
5/14/2021Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to B from B+ on 5/14/2021 due to a significant decline in the growth index and total return index.
Integrated Biopharma, Inc. (INBP) was downgraded to B from B+ on 5/14/2021 due to a significant decline in the growth index and total return index.
B
Buy
5/7/2021Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to B+ from B on 5/7/2021 due to a noticeable increase in the total return index, volatility index and growth index.
Integrated Biopharma, Inc. (INBP) was upgraded to B+ from B on 5/7/2021 due to a noticeable increase in the total return index, volatility index and growth index.
B
Buy
2/12/2021Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to B from B- on 2/12/2021 due to a noticeable increase in the growth index, efficiency index and total return index. Earnings per share increased from $0.03 to $0.04, net income increased 17.58% from $1.04M to $1.22M, and total capital increased 10.43% from $16.14M to $17.82M.
Integrated Biopharma, Inc. (INBP) was upgraded to B from B- on 2/12/2021 due to a noticeable increase in the growth index, efficiency index and total return index. Earnings per share increased from $0.03 to $0.04, net income increased 17.58% from $1.04M to $1.22M, and total capital increased 10.43% from $16.14M to $17.82M.
B
Buy
2/1/2021Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to B- from B on 2/1/2021 due to a decline in the total return index, valuation index and volatility index.
Integrated Biopharma, Inc. (INBP) was downgraded to B- from B on 2/1/2021 due to a decline in the total return index, valuation index and volatility index.
B
Buy
12/14/2020Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to B from B- on 12/14/2020 due to an increase in the total return index and volatility index.
Integrated Biopharma, Inc. (INBP) was upgraded to B from B- on 12/14/2020 due to an increase in the total return index and volatility index.
B
Buy
11/27/2020Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to B- from C on 11/27/2020 due to an increase in the growth index, volatility index and solvency index. Operating cash flow increased 186.79% from -$2.21M to $1.92M, EBIT increased 144.17% from $618 to $1.51M, and debt to equity declined from 1.45 to 0.96.
Integrated Biopharma, Inc. (INBP) was upgraded to B- from C on 11/27/2020 due to an increase in the growth index, volatility index and solvency index. Operating cash flow increased 186.79% from -$2.21M to $1.92M, EBIT increased 144.17% from $618 to $1.51M, and debt to equity declined from 1.45 to 0.96.
C
Hold
6/23/2020Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 6/23/2020 due to a decline in the valuation index.
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 6/23/2020 due to a decline in the valuation index.
C
Hold
4/29/2020Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C+ from C on 4/29/2020 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from $0.01 to $0.03, EBIT increased 153.15% from $476 to $1.21M, and the quick ratio increased from 0.31 to 0.4.
Integrated Biopharma, Inc. (INBP) was upgraded to C+ from C on 4/29/2020 due to a noticeable increase in the growth index, total return index and solvency index. Earnings per share increased from $0.01 to $0.03, EBIT increased 153.15% from $476 to $1.21M, and the quick ratio increased from 0.31 to 0.4.
C
Hold
9/23/2019Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 9/23/2019 due to a noticeable decline in the total return index, growth index and efficiency index. Earnings per share declined from $0.03 to $0.0102, net income declined 61% from $923 to $360, and EBIT declined 53.6% from $1.24M to $574.
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 9/23/2019 due to a noticeable decline in the total return index, growth index and efficiency index. Earnings per share declined from $0.03 to $0.0102, net income declined 61% from $923 to $360, and EBIT declined 53.6% from $1.24M to $574.
C
Hold
8/29/2019Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C+ from C on 8/29/2019 due to a significant increase in the total return index, solvency index and growth index. Earnings per share increased from $0.0084 to $0.03, EBIT increased 154% from $487 to $1.24M, and operating cash flow increased 140.81% from -$1.51M to $615.
Integrated Biopharma, Inc. (INBP) was upgraded to C+ from C on 8/29/2019 due to a significant increase in the total return index, solvency index and growth index. Earnings per share increased from $0.0084 to $0.03, EBIT increased 154% from $487 to $1.24M, and operating cash flow increased 140.81% from -$1.51M to $615.
C
Hold
3/5/2019Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 3/5/2019 due to a major increase in the valuation index, efficiency index and volatility index. Net income increased 54.72% from $159 to $246, and total capital increased 12.56% from $12.7M to $14.29M.
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 3/5/2019 due to a major increase in the valuation index, efficiency index and volatility index. Net income increased 54.72% from $159 to $246, and total capital increased 12.56% from $12.7M to $14.29M.
C
Hold
11/29/2018Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C- from C on 11/29/2018 due to a decline in the total return index, volatility index and efficiency index.
Integrated Biopharma, Inc. (INBP) was downgraded to C- from C on 11/29/2018 due to a decline in the total return index, volatility index and efficiency index.
C
Hold
11/14/2018Upgraded
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 11/14/2018 due to a significant increase in the valuation index, growth index and efficiency index. Operating cash flow increased 438.86% from -$175 to $593.
Integrated Biopharma, Inc. (INBP) was upgraded to C from C- on 11/14/2018 due to a significant increase in the valuation index, growth index and efficiency index. Operating cash flow increased 438.86% from -$175 to $593.
C
Hold
9/21/2018Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C- from C on 9/21/2018 due to a significant decline in the valuation index, growth index and total return index. Operating cash flow declined 124.89% from $703 to -$175, earnings per share declined from $0.0132 to $0.0114, and EBIT declined 5.3% from $660 to $625.
Integrated Biopharma, Inc. (INBP) was downgraded to C- from C on 9/21/2018 due to a significant decline in the valuation index, growth index and total return index. Operating cash flow declined 124.89% from $703 to -$175, earnings per share declined from $0.0132 to $0.0114, and EBIT declined 5.3% from $660 to $625.
C
Hold
5/15/2017Downgrade
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 5/15/2017 due to a decline in the efficiency index. Total capital declined 0.7% from $7.15M to $7.1M.
Integrated Biopharma, Inc. (INBP) was downgraded to C from C+ on 5/15/2017 due to a decline in the efficiency index. Total capital declined 0.7% from $7.15M to $7.1M.
C
Hold
9/15/2016Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 9/15/2016 due to a significant increase in the valuation index, volatility index and efficiency index. Net income increased 2,163.64% from $33 to $747, and total capital increased 9.24% from $6.71M to $7.33M.
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 9/15/2016 due to a significant increase in the valuation index, volatility index and efficiency index. Net income increased 2,163.64% from $33 to $747, and total capital increased 9.24% from $6.71M to $7.33M.
C
Hold
5/23/2016Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to C from C- on 5/23/2016 due to a significant increase in the valuation index and growth index.
Integrated Biopharma Inc. (INBP) was upgraded to C from C- on 5/23/2016 due to a significant increase in the valuation index and growth index.
C
Hold
5/16/2016Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to C- from D+ on 5/16/2016 due to a noticeable increase in the growth index, efficiency index and total return index. EBIT increased 167.86% from $168 to $450, earnings per share increased from -$0.003 to $0.0016, and net income increased 152.38% from -$63 to $33.
Integrated Biopharma Inc. (INBP) was upgraded to C- from D+ on 5/16/2016 due to a noticeable increase in the growth index, efficiency index and total return index. EBIT increased 167.86% from $168 to $450, earnings per share increased from -$0.003 to $0.0016, and net income increased 152.38% from -$63 to $33.
D
Sell
4/28/2016Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to D+ from D on 4/28/2016 due to a noticeable increase in the total return index.
Integrated Biopharma Inc. (INBP) was upgraded to D+ from D on 4/28/2016 due to a noticeable increase in the total return index.
D
Sell
4/13/2016Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to D from D+ on 4/13/2016 due to a noticeable decline in the total return index and volatility index.
Integrated Biopharma Inc. (INBP) was downgraded to D from D+ on 4/13/2016 due to a noticeable decline in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to D+ from C- on 3/11/2016 due to a major decline in the volatility index.
Integrated Biopharma Inc. (INBP) was downgraded to D+ from C- on 3/11/2016 due to a major decline in the volatility index.
C
Hold
2/19/2016Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to C- from C+ on 2/19/2016 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 465.14% from $436 to -$1.59M, earnings per share declined from $0.01 to -$0.003, and net income declined 126.14% from $241 to -$63.
Integrated Biopharma Inc. (INBP) was downgraded to C- from C+ on 2/19/2016 due to a significant decline in the valuation index, growth index and efficiency index. Operating cash flow declined 465.14% from $436 to -$1.59M, earnings per share declined from $0.01 to -$0.003, and net income declined 126.14% from $241 to -$63.
C
Hold
2/17/2016Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to C+ from B- on 2/17/2016 due to a decline in the total return index.
Integrated Biopharma Inc. (INBP) was downgraded to C+ from B- on 2/17/2016 due to a decline in the total return index.
B
Buy
1/29/2016Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to B- from C+ on 1/29/2016 due to an increase in the total return index.
Integrated Biopharma Inc. (INBP) was upgraded to B- from C+ on 1/29/2016 due to an increase in the total return index.
C
Hold
1/12/2016Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to C+ from B- on 1/12/2016 due to a decline in the total return index and valuation index.
Integrated Biopharma Inc. (INBP) was downgraded to C+ from B- on 1/12/2016 due to a decline in the total return index and valuation index.
B
Buy
12/28/2015Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to B- from C+ on 12/28/2015 due to a substantial increase in the growth index, total return index and efficiency index. EBIT increased 573.61% from $72 to $485, and total revenue increased 5.6% from $8.94M to $9.45M.
Integrated Biopharma Inc. (INBP) was upgraded to B- from C+ on 12/28/2015 due to a substantial increase in the growth index, total return index and efficiency index. EBIT increased 573.61% from $72 to $485, and total revenue increased 5.6% from $8.94M to $9.45M.
C
Hold
9/4/2015Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 9/4/2015 due to a substantial increase in the efficiency index, valuation index and growth index. EBIT increased 500% from $12 to $72, and net income increased 3.77% from -$106 to -$110.
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 9/4/2015 due to a substantial increase in the efficiency index, valuation index and growth index. EBIT increased 500% from $12 to $72, and net income increased 3.77% from -$106 to -$110.
C
Hold
2/20/2015Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to C from D+ on 2/20/2015 due to a significant increase in the valuation index, efficiency index and growth index. Earnings per share increased from $0.0101 to $0.0259, operating cash flow increased 96.97% from -$495 to -$975, and net income increased 35.73% from $403 to $547.
Integrated Biopharma Inc. (INBP) was upgraded to C from D+ on 2/20/2015 due to a significant increase in the valuation index, efficiency index and growth index. Earnings per share increased from $0.0101 to $0.0259, operating cash flow increased 96.97% from -$495 to -$975, and net income increased 35.73% from $403 to $547.
D
Sell
11/11/2014Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to D+ from C- on 11/11/2014 due to a decline in the total return index and volatility index.
Integrated Biopharma Inc. (INBP) was downgraded to D+ from C- on 11/11/2014 due to a decline in the total return index and volatility index.
C
Hold
11/7/2014Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to C- from C on 11/7/2014 due to a major decline in the growth index, valuation index and volatility index. Earnings per share declined from -$0.0054 to $0.01.
Integrated Biopharma Inc. (INBP) was downgraded to C- from C on 11/7/2014 due to a major decline in the growth index, valuation index and volatility index. Earnings per share declined from -$0.0054 to $0.01.
C
Hold
9/10/2014Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to C from C+ on 9/10/2014 due to a significant decline in the valuation index, total return index and efficiency index. Net income declined 74.67% from -$450 to -$114.
Integrated Biopharma Inc. (INBP) was downgraded to C from C+ on 9/10/2014 due to a significant decline in the valuation index, total return index and efficiency index. Net income declined 74.67% from -$450 to -$114.
C
Hold
9/2/2014Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 9/2/2014 due to a noticeable increase in the total return index and valuation index.
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 9/2/2014 due to a noticeable increase in the total return index and valuation index.
C
Hold
8/13/2014Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to C from C+ on 8/13/2014 due to a decline in the total return index, volatility index and valuation index.
Integrated Biopharma Inc. (INBP) was downgraded to C from C+ on 8/13/2014 due to a decline in the total return index, volatility index and valuation index.
C
Hold
5/30/2014Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 5/30/2014 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from -1.5 to -1.34.
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 5/30/2014 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from -1.5 to -1.34.
C
Hold
5/1/2014Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to C from C+ on 5/1/2014 due to a decline in the total return index and volatility index.
Integrated Biopharma Inc. (INBP) was downgraded to C from C+ on 5/1/2014 due to a decline in the total return index and volatility index.
C
Hold
4/10/2014Upgraded
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 4/10/2014 due to a noticeable increase in the total return index.
Integrated Biopharma Inc. (INBP) was upgraded to C+ from C on 4/10/2014 due to a noticeable increase in the total return index.
C
Hold
3/26/2014Downgrade
Integrated Biopharma Inc. (INBP) was downgraded to C from C+ on 3/26/2014 due to a noticeable decline in the total return index and volatility index.
Integrated Biopharma Inc. (INBP) was downgraded to C from C+ on 3/26/2014 due to a noticeable decline in the total return index and volatility index.
OTC PK
03/07/2025 2:36PM Eastern
Quotes delayed
